Concepedia

Giorgio Caravatti

GC

Statistics

Publications

44

Citations

3.5K

H-Index

29

Active since

1983

Affiliations

Novartis (Switzerland)(Current)

Novartis Institutes for BioMedical Research

Giorgio Caravatti is an author at Novartis (Switzerland) specializing in pharmacology, medicinal chemistry, and drug discovery.

Publications per year

1983–2022

44

Publications

44

Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

Christine Fritsch, Alan Huang, Christian Chatenay‐Rivauday et al. · Molecular Cancer Therapeutics · 2014 · 496 citations

Medicine, Oncology, Pharmacology +16

Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation

Pascal Furet, Vito Guagnano, Robin A. Fairhurst et al. · Bioorganic & Medicinal Chemistry Letters · 2013 · 470 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +11

A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and <i>In vitro</i> anti‐proliferative as well as <i>In vivo</i> anti‐tumor activity

Thomas Meyer, Urs Regenass, Doriano Fabbro et al. · International Journal of Cancer · 1989 · 408 citations

Medicine, Medicinal Chemistry, Pharmacology +13

Peter Traxler, Peter R. Allegrini, Ralf Brandt et al. · Cancer Research · 2004 · 318 citations

Medicine, Oncology, Pharmacology +17

The RET Kinase Inhibitor NVP-AST487 Blocks Growth and Calcitonin Gene Expression through Distinct Mechanisms in Medullary Thyroid Cancer Cells

Nagako Akeno-Stuart, Michelle Croyle, Jeffrey A. Knauf et al. · Cancer Research · 2007 · 112 citations

Medicine, Oncology, Pharmacology +16

1–5 of 44